InMed Pharmaceuticals Inc
For the period ended Dec 31, 2024. Filed Feb 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2024 · Filed Feb 12, 2025
INM$15.56+17.8%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
For the Six Months ended December 31, 2024 and 2023
| 2024 · 2023 | ||||
|---|---|---|---|---|
| $ · $ | ||||
| Cash provided by (used in): | ||||
| Operating Activities | ||||
| Net loss | (4,252,892) | (4,015,013) | ||
| Items not requiring cash: | ||||
| Amortization and depreciation | 107,782 | 110,063 | ||
| Share-based compensation | 52,123 | 43,455 | ||
| Amortization of ROU assets | 166,277 | 191,909 | ||
| Interest income received on short-term investments | (874) | (1,019) | ||
| Unrealized foreign exchange loss | 20,338 | 978 | ||
| Inventory write-down | - | 263,404 | ||
| Changes in operating assets and liabilities: | ||||
| Inventories | 140,968 | 608,113 | ||
| Prepaids and other currents assets | (166,237) | (614,944) | ||
| Other non-current assets | - | 4,908 | ||
| Accounts receivable | 90,269 | (112,470) | ||
| Accounts payable and accrued liabilities | (282,778) | (321,106) | ||
| Deferred rent | - | 12,485 | ||
| Operating lease obligations | (203,924) | (193,109) | ||
| Total cash used in operating activities | (4,328,948) | (4,022,346) | ||
| Investing Activities | ||||
| Sale of short-term investments | 24,002 | 21,317 | ||
| Purchase of short-term investments | (24,002) | (21,317) | ||
| Purchase of property and equipment | - | (9,291) | ||
| Total cash used in investing activities | - | (9,291) | ||
| Financing Activities | ||||
| Proceeds from the private placement | 1,426,216 | 5,216,193 | ||
| Private placement issuance costs | (249,456) | (562,151) | ||
| Total cash provided by financing activities | 1,176,760 | 4,654,042 | ||
| (Decrease) increase in cash during the period | (3,152,188) | 622,405 | ||
| Cash and cash equivalents beginning of the period | 6,571,610 | 8,912,517 | ||
| Cash and cash equivalents end of the period | 3,419,422 | 9,534,922 | ||
| SUPPLEMENTARY CASH FLOW INFORMATION: | ||||
| Cash Paid During the Period for: | ||||
| Income Taxes | $ | - | $ | - |
| Interest | $ | - | $ | - |
| SUPPLEMENTARY DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: | ||||
| Fair value of warrant modification recorded as equity issuance costs | $ | - | 3,508,749 | |
| Preferred investment options to its placement agent | $ | - | 325,699 | |
| Recognition of ROU asset and corresponding operating lease liability | $187,223 | $968,376 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.